WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1999042592) METHODS FOR DESIGNING INHIBITORS OF SERINE/THREONINE KINASES AND TYROSINE KINASES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1999/042592    International Application No.:    PCT/US1999/003181
Publication Date: 26.08.1999 International Filing Date: 16.02.1999
Chapter 2 Demand Filed:    20.09.1999    
IPC:
C12N 9/12 (2006.01)
Applicants: VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 130 Waverly Street Cambridge, MA 02139-4242 (US)
Inventors: SU, Michael, S.; (US).
FOX, Edward; (US).
WILSON, Keith, P.; (US).
GERMANN, Ursula, A.; (US)
Agent: HALEY, James, F.; Fish & Neave 1251 Avenue of the Americas New York, NY 10020 (US)
Priority Data:
09/025,580 18.02.1998 US
Title (EN) METHODS FOR DESIGNING INHIBITORS OF SERINE/THREONINE KINASES AND TYROSINE KINASES
(FR) PROCEDES SERVANT A DEVELOPPER DES INHIBITEURS DE SERINE/THREONINE KINASES ET DE TYROSINE KINASES
Abstract: front page image
(EN)The invention relates to methods for designing inhibitors of serine/threonine kinases and tyrosine kinases, particularly MAP kinases, through the use of ATP-binding site mutants of those kinases. The methods of this invention take advantage of the fact that the mutant kinases are capable of binding inhibitory compounds of other kinases with greater affinity than the corresponding wild-type kinase. The invention further relates to the mutant kinases themselves and crystallizable co-complexes of the mutant kinase and the inhibitory compound.
(FR)L'invention concerne des procédés servant à développer des inhibiteurs de sérine/thréonine kinases et de tyrosine kinases, en particulier des MAP kinases, au moyen de mutantes du site de fixation à ATP de ces kinases. Ces procédés sont avantageusement basés sur le fait que les kinases mutantes sont capables de se fixer à des composés inhibiteurs d'autres kinases avec une affinité supérieure à celle de la kinase correspondante de type sauvage. Elle concerne, de plus, les kinases mutantes proprement dites et des complexes associés cristallisables de la kinase mutante et du composé inhibiteur.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)